Data as of .
Genomics and biotech innovation ETFs: what each one actually holds
4 funds, measured by holdings rather than by name. The typical fund carries 18% of its weight in S&P 500 names.
| Ticker | Fund | Issuer | In the S&P 500 | Active share | Total return 1Y | vs S&P 500 | Fee |
|---|---|---|---|---|---|---|---|
| ARKG | ARK Genomic Revolution ETF | ARK | 3.9% | 98.5% | +89.3% | +69.4 pts | 0.75% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | iShares | 21.4% | 99.1% | +78.0% | +58.0 pts | 0.47% |
| GNOM | Global X Genomics & Biotechnology ETF | Global X | 17.9% | 97.6% | +75.7% | +55.8 pts | 0.50% |
| XDNA | Kelly CRISPR & Gene Editing Technology ETF | not published | not published | not published | +0.0% | −20.0 pts | not published |
Where to next
ETFIQ is an independent publisher and makes no recommendations; every figure is stated arithmetic on published data. Standards and sources
Cite this page. ETFIQ, Genomics and biotech innovation ETFs: what each one actually holds, data as of Sep 4, 2026. https://etfiq.com/themes/genomics.html Free to use with attribution; the underlying files are at Open data.